JP2020530993A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530993A5
JP2020530993A5 JP2020505194A JP2020505194A JP2020530993A5 JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5 JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020505194 A JP2020505194 A JP 2020505194A JP 2020530993 A5 JP2020530993 A5 JP 2020530993A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequence
cell
expressed
noi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020505194A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530993A (ja
Filing date
Publication date
Priority claimed from GBGB1712407.4A external-priority patent/GB201712407D0/en
Priority claimed from GBGB1806372.7A external-priority patent/GB201806372D0/en
Application filed filed Critical
Priority claimed from PCT/GB2018/052204 external-priority patent/WO2019025800A1/en
Publication of JP2020530993A publication Critical patent/JP2020530993A/ja
Publication of JP2020530993A5 publication Critical patent/JP2020530993A5/ja
Priority to JP2023057340A priority Critical patent/JP2023076572A/ja
Pending legal-status Critical Current

Links

JP2020505194A 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 Pending JP2020530993A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023057340A JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1712407.4A GB201712407D0 (en) 2017-08-02 2017-08-02 Cell
GB1712407.4 2017-08-02
GBGB1806372.7A GB201806372D0 (en) 2018-04-19 2018-04-19 Cell
GB1806372.7 2018-04-19
PCT/GB2018/052204 WO2019025800A1 (en) 2017-08-02 2018-08-01 CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057340A Division JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Publications (2)

Publication Number Publication Date
JP2020530993A JP2020530993A (ja) 2020-11-05
JP2020530993A5 true JP2020530993A5 (enExample) 2021-07-26

Family

ID=63371717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505194A Pending JP2020530993A (ja) 2017-08-02 2018-08-01 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023057340A Pending JP2023076572A (ja) 2017-08-02 2023-03-31 キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞

Country Status (7)

Country Link
US (1) US20210130775A1 (enExample)
EP (1) EP3662055A1 (enExample)
JP (2) JP2020530993A (enExample)
CN (1) CN111164203A (enExample)
AU (1) AU2018311345A1 (enExample)
CA (1) CA3071495A1 (enExample)
WO (1) WO2019025800A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
AU2020232789B2 (en) * 2019-03-06 2026-04-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2021028359A1 (en) * 2019-08-09 2021-02-18 Sangamo Therapeutics France Controlled expression of chimeric antigen receptors in t cells
EP4017510A4 (en) * 2019-08-20 2023-11-22 Senti Biosciences, Inc. CHIMERIC INHIBITOR RECEPTOR
CN120605327A (zh) * 2019-11-06 2025-09-09 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
CA3176697A1 (en) * 2020-05-11 2021-11-18 Doughlas J. JOLLY Vectors and methods for in vivo transduction
GB202013466D0 (en) * 2020-08-27 2020-10-14 Inst De Medicina Molecular Joaeo Lobo Antunes Genetic construct
EP4455157A1 (en) * 2023-04-27 2024-10-30 Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps Polynuceotide for t cell specific transgene expression
WO2025226608A1 (en) * 2024-04-22 2025-10-30 The Johns Hopkins University Immunotoxin-armored immune effector cells and uses thereof
WO2026085295A1 (en) * 2024-10-16 2026-04-23 The Cleveland Clinic Foundation Kynurenine responsive and degrading bacteria

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
GB201206559D0 (en) * 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
EP3858379A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201322798D0 (en) * 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11385233B2 (en) * 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
HRP20240357T1 (hr) * 2014-12-24 2024-06-07 Autolus Limited Stanica
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
GB201504840D0 (en) * 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
MX2017015239A (es) * 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
US10286092B2 (en) * 2015-08-25 2019-05-14 Ucl Business Plc Detecting a therapeutic cell
US11098283B2 (en) * 2015-08-25 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-Myb
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
JP7054924B2 (ja) * 2015-09-23 2022-04-15 サイトイミューン セラピューティクス， インコーポレイテッド 免疫療法のためのｆｌｔ３指向ｃａｒ細胞
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
WO2017075537A1 (en) * 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
SG11201901757YA (en) * 2016-09-08 2019-03-28 Bluebird Bio Inc Pd-1 homing endonuclease variants, compositions, and methods of use
CA3042613A1 (en) * 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
GB201621891D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Transcription system
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell
GB201707779D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
CA3063695A1 (en) * 2017-05-17 2018-11-22 Seattle Children's Hospital (Dba Seattle Children's Research Institute Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
JP7621795B2 (ja) * 2017-10-19 2025-01-27 セレクティス 改善された免疫細胞療法のためのｎｋ阻害物質遺伝子の標的指向遺伝子組み込み
GB201718697D0 (en) * 2017-11-13 2017-12-27 Autolus Ltd Cell
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
GB201807862D0 (en) * 2018-05-15 2018-06-27 Ucl Business Plc Chimeric antigen receptor
WO2019220109A1 (en) * 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
SG11202102781UA (en) * 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
GB201816522D0 (en) * 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
EP3893923A2 (en) * 2018-12-14 2021-10-20 Autolus Limited Cell
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201906202D0 (en) * 2019-05-02 2019-06-19 Autolus Ltd Cell
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle

Similar Documents

Publication Publication Date Title
Khan et al. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Labanieh et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Sagiv et al. NKG2D ligands mediate immunosurveillance of senescent cells
Nebral et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia
Kudo-Saito et al. CCL2 is critical for immunosuppression to promote cancer metastasis
AU2016283102B2 (en) Chimeric antigen receptors (CARs), compositions and methods of use thereof
BR112021007626A2 (pt) Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
Su et al. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs
JP6546160B2 (ja) 腫瘍細胞による免疫抑制を低下させるための方法および組成物
CN113015744A (zh) 单链嵌合多肽和多链嵌合多肽以及其用途
Ito et al. mTOR complex signaling through the SEMA4A–Plexin B2 axis is required for optimal activation and differentiation of CD8+ T cells
AU2018268087B2 (en) Compositions and methods for cell targeting therapies
JP2023076572A (ja) キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
RU2017132293A (ru) Химерный белок
CN111246861A (zh) 扩增表达重组受体的细胞的试剂
EP3191592A1 (en) Inhibition of prmt5 to treat mtap-deficiency-related diseases
Lindner et al. The miR‐15 family reinforces the transition from proliferation to differentiation in pre‐B cells
AU2023354543A1 (en) Compositions and methods for enhancing adoptive t cell therapeutics
CN110461881A (zh) 嵌合抗原受体
Birley et al. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers
Jaeger-Ruckstuhl et al. TNIK signaling imprints CD8+ T cell memory formation early after priming
Yi et al. L1 cell adhesion molecule induces melanoma cell motility by activation of mitogen-activated protein kinase pathways
Xu et al. Advances in the multi-omics landscape of follicular lymphoma
KR20230143135A (ko) Cd19+, cd20+ 또는 cd22+ 종양 또는 b-세포 유래 자가-면역질환을 치료하기 위한 car t-세포
KR20240090127A (ko) 개선된 면역치료법을 위한 방법 및 조성물